Compare Apple Inc (AAPL) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Becton Dickinson and Co — how do they compare? Apple Inc trades at $311.4 (market cap $4.56T), while Becton Dickinson and Co trades at $151.6 (market cap $43.07B). The key difference: Apple Inc is far larger — about 105.9× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| AAPL | BDX | |
|---|---|---|
Market Cap | $4.56T | $43.07B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $185.39 |
52-Week Low | $202.38 | $135.49 |
Enterprise Value | $4.58T | $59.53B |
Dividend Yield | 0.35% | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $310.09, down 0.82% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.01 exceeding the $1.95 estimate. Revenue for 2025 reached $416.16 billion, driving a net income margin of 26.91%. Analysts maintain a consensus buy rating with a $329.62 price target, citing Apple's massive device base as an AI opportunity.
The outlook remains positive given earnings momentum and a $0.27 dividend, but risks include potential Q2 2026 earnings miss concerns and union disputes. Valuation multiples like P/E of 37.61 suggest premium pricing, requiring sustained growth to justify upside. Institutional holdings show mixed activity, with some trimming positions amid high RSI levels indicating overbought conditions near-term.
BDX trades at $156.30, down 1.13% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations for Q1 2026, and the company maintains stable revenue growth, reaching $21.84B in 2025. Positive news highlights innovation in medical technology and dividend reliability, supporting a mixed but leaning positive analyst view.
Outlook is cautiously optimistic with a consensus price target of $172.33 offering ~10% upside. Risks include hospital spending caution and reimbursement uncertainty, but strong cash flow and product launches provide growth catalysts. The stock presents a balanced opportunity for dividend-focused investors amid moderate volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
